eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc. (EFTR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
eftr · stock forecast · 6 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$10.00
Consensus
$5.50
+2749900.0% upside
Low
$1.00
Median: $5.5 · Last Close: $0.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.00 | ↑ 0.00% |
1-day model range: $0–$0. Peak: $0 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · EFTR · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-03-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-02-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-11-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-05-25 | Stifel | Upgrade ↑ | Hold→Buy |
| 2023-05-09 | Credit Suisse | Maintains | Outperform→Outperform |
| 2023-03-08 | Credit Suisse | Maintains | Outperform→Outperform |
| 2023-01-08 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2023-01-05 | Credit Suisse | Maintains | Outperform→Outperform |
| 2022-11-16 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2022-08-10 | JMP Securities | Maintains | Market Outperform→Market Outperform |
Wall Street analysts have recently issued updated ratings on eFFECTOR Therapeutics, Inc. (EFTR) stock. Of the recent 20 rating actions, 2 were upgrades and 1 were downgrades. 6 analysts currently cover EFTR.
Analyst Recommendation Trends
EFTR analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
EPS This Year
$-12.42
EPS Next Year
$-6.17
↓ 50.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast EFTR EPS of $-12.42 for the current fiscal year, based on estimates from 1 analysts. The EFTR revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The EFTR stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus EFTR price target is $5.50 (+2749900.0% upside), with an analyst consensus of Buy.
The EFTR short-term stock prediction for tomorrow is $0.00 (+0.00%).
eFFECTOR Therapeutics, Inc. trades on OTC under the ticker EFTR. The EFTR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
EFTR forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month EFTR price target is $5.50, with a high forecast of $10.00 and a low of $1.00. The median price target is shown in the chart above when available. This implies +2749900.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.